Intelence and Triumeq

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Etravirine may reduce the blood levels of dolutegravir, which may make the medication less effective in treating HIV infection. You should not be taking these medications together unless you are also receiving either atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in your HIV regimen, since adding these agents helps to diminish the interaction between etravirine and dolutegravir. Contact a healthcare professional if you have any questions or concerns, and seek immediate medical attention if your condition worsens or you develop new infections during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with etravirine may significantly decrease the plasma concentrations of dolutegravir. The exact mechanism of interaction has not been established, but may rely partially on etravirine induction of dolutegravir metabolism via CYP450 3A4 and UGT1A1. In 16 study subjects, administration of dolutegravir 50 mg once daily with etravirine 200 mg twice daily decreased dolutegravir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin; 24 hours postdose) by 52%, 71% and 88%, respectively, compared to administration without etravirine. These effects were mitigated by coadministration of darunavir/ritonavir or lopinavir/ritonavir. When the same dosage of dolutegravir was given with etravirine 200 mg and darunavir/ritonavir 600 mg/100 mg twice daily to 9 study subjects, dolutegravir Cmax, AUC and Cmin decreased by just 12%, 25% and 37%, respectively. When given with etravirine 200 mg plus lopinavir/ritonavir 400 mg/100 mg twice daily to 8 study subjects, dolutegravir Cmax, AUC and Cmin increased by 7%, 11% and 28%, respectively. Although not studied, the interaction between dolutegravir and etravirine is also expected to be mitigated by atazanavir/ritonavir. Using cross-study comparisons to historical pharmacokinetic data, dolutegravir did not appear to affect the pharmacokinetics of etravirine, atazanavir, darunavir, lopinavir, or ritonavir.

MANAGEMENT: Dolutegravir should not be used with etravirine unless also coadministered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. Concomitant use of etravirine with the fixed-dose combination products containing abacavir/dolutegravir/lamivudine or dolutegravir/lamivudine is not recommended.

Intelence

Generic Name: etravirine

Brand name: Intelence

Synonyms: n.a.

What is Intelence?

Triumeq

Generic Name: abacavir / dolutegravir / lamivudine

Brand name: Triumeq

Synonyms: n.a.

What is Triumeq?